Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

Current treatment strategies for type 2 diabetes mellitus (T2DM) are based on using safe and effective hypoglycaemic agents for preventing diabetic vascular complications and reducing the risks associated with weight gain and hypoglycaemia. These goals may be achieved using new agents with a fundame...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lyudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Karina Oganesovna Galstyan
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2014
Materias:	diabetes glycated haemoglobin dpp-4 inhibitors gosogliptin vildagliptin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/fb519b359fdd45229eac312deddbbffd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb519b359fdd45229eac312deddbbffd
record_format	dspace
spelling	oai:doaj.org-article:fb519b359fdd45229eac312deddbbffd2021-11-14T09:00:19ZInitial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia2072-03512072-037810.14341/DM2014481-86https://doaj.org/article/fb519b359fdd45229eac312deddbbffd2014-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6740https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Current treatment strategies for type 2 diabetes mellitus (T2DM) are based on using safe and effective hypoglycaemic agents for preventing diabetic vascular complications and reducing the risks associated with weight gain and hypoglycaemia. These goals may be achieved using new agents with a fundamentally new mechanism of action: inhibitors of dipeptidyl peptidase-4 (DPP-4i). However, the wide distribution of this enzyme in the body is associated with extraglycaemic DPP-4i effects, both positive and negative. Thus, it is important to develop and implement new DPP-4i agents for clinical practice. Aim. To investigate the efficacy and safety of a novel DPP-4i, gosogliptin, for use as monotherapy and in combination with metformin vs. vildagliptin as monotherapy and in combination with metformin for patients with drug-naive type 2 diabetes in a multicentre, open, randomized clinical trial. Materials and methods. We enrolled 299 drug-naive type 2 diabetes patients; 149 patients were randomized to receive gosogliptin and 150 patients received tovildagliptin. These groups had similar baseline characteristics. After randomization, 12 weeks of monotherapy was administered to both groups. Further, it was decided to continue the monotherapy or in combination with metformin, depending on each patient. The results after the first 12 weeks are presented in this paper. Results. After 12 weeks of monotherapy, HbA1c levels decreased significantly from 8.61% to 7.41% (pLyudmila Viktorovna NedosugovaNina Alexandrovna PetuninaKarina Oganesovna GalstyanEndocrinology Research Centrearticlediabetesglycated haemoglobindpp-4 inhibitorsgosogliptinvildagliptinNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 17, Iss 4, Pp 81-86 (2014)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	diabetes glycated haemoglobin dpp-4 inhibitors gosogliptin vildagliptin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	diabetes glycated haemoglobin dpp-4 inhibitors gosogliptin vildagliptin Nutritional diseases. Deficiency diseases RC620-627 Lyudmila Viktorovna Nedosugova Nina Alexandrovna Petunina Karina Oganesovna Galstyan Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
description	Current treatment strategies for type 2 diabetes mellitus (T2DM) are based on using safe and effective hypoglycaemic agents for preventing diabetic vascular complications and reducing the risks associated with weight gain and hypoglycaemia. These goals may be achieved using new agents with a fundamentally new mechanism of action: inhibitors of dipeptidyl peptidase-4 (DPP-4i). However, the wide distribution of this enzyme in the body is associated with extraglycaemic DPP-4i effects, both positive and negative. Thus, it is important to develop and implement new DPP-4i agents for clinical practice. Aim. To investigate the efficacy and safety of a novel DPP-4i, gosogliptin, for use as monotherapy and in combination with metformin vs. vildagliptin as monotherapy and in combination with metformin for patients with drug-naive type 2 diabetes in a multicentre, open, randomized clinical trial. Materials and methods. We enrolled 299 drug-naive type 2 diabetes patients; 149 patients were randomized to receive gosogliptin and 150 patients received tovildagliptin. These groups had similar baseline characteristics. After randomization, 12 weeks of monotherapy was administered to both groups. Further, it was decided to continue the monotherapy or in combination with metformin, depending on each patient. The results after the first 12 weeks are presented in this paper. Results. After 12 weeks of monotherapy, HbA1c levels decreased significantly from 8.61% to 7.41% (p
format	article
author	Lyudmila Viktorovna Nedosugova Nina Alexandrovna Petunina Karina Oganesovna Galstyan
author_facet	Lyudmila Viktorovna Nedosugova Nina Alexandrovna Petunina Karina Oganesovna Galstyan
author_sort	Lyudmila Viktorovna Nedosugova
title	Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
title_short	Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
title_full	Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
title_fullStr	Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
title_full_unstemmed	Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
title_sort	initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in russia
publisher	Endocrinology Research Centre
publishDate	2014
url	https://doaj.org/article/fb519b359fdd45229eac312deddbbffd
work_keys_str_mv	AT lyudmilaviktorovnanedosugova initialinvestigationofefficacyandsafetyofanewdipeptidylpeptidase4inhibitorgosogliptinfortype2diabetesinrussia AT ninaalexandrovnapetunina initialinvestigationofefficacyandsafetyofanewdipeptidylpeptidase4inhibitorgosogliptinfortype2diabetesinrussia AT karinaoganesovnagalstyan initialinvestigationofefficacyandsafetyofanewdipeptidylpeptidase4inhibitorgosogliptinfortype2diabetesinrussia
_version_	1718429566677024768

Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia

Ejemplares similares